Latest Breaking News On - வரவிருக்கும் ஏவுதல் - Page 2 : comparemela.com

TM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany Update on OTL-200 U.S. BLA Filing Strategy for MLD on Track for Mid-2021 Following Type B RMAT Meeting with FDA Recent Publications, Including ADA-SCID Dataset in NEJM and Multiple Oral Presentations at ASGCT, Highlight Broad and Innovative Potential of HSC Gene Therapy Cash and Investments of Approximately $300M Provide Runway into First Half 2023 Following $150M Financing in February 2021 BOSTON and LONDON, May 13, 2021 (GLOBE NEWSWIRE) Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reported financial results for the quarter ended March 31, 2021, as well as recent business updates and upcoming milestones.

United statesUnited kingdomCity ofBobby gasparGen ilacGemeinsamer bundeausschussEuropean medicines agencyAmerican society for geneEuropean hematology associationDrug administrationCommercial activities advancingUpcoming launchEligible patientsMultiple oral presentationsHighlight broadInnovative potential